Source 1primary paper2025MED
Toolkit/nanoparticle tracking analysis
nanoparticle tracking analysis
Also known as: NTA
Taxonomy: Technique Branch / Method. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
AF4-MALS was shown to be a suitable surrogate for nanoparticle tracking analysis, as the 90° light scattering peak area exhibited a strong linear correlation with total particle concentration.
Usefulness & Problems
Why this is useful
Nanoparticle tracking analysis is used here as the comparator method for total particle concentration. The paper evaluates whether AF4-MALS can substitute for it.; total particle quantification; Nanoparticle tracking was used to analyze circulating plasma EV characteristics, specifically size and concentration. These measurements were then used as model features.; characterizing circulating plasma EV size; characterizing circulating plasma EV concentration
Source:
Nanoparticle tracking analysis is used here as the comparator method for total particle concentration. The paper evaluates whether AF4-MALS can substitute for it.
Source:
total particle quantification
Source:
Nanoparticle tracking was used to analyze circulating plasma EV characteristics, specifically size and concentration. These measurements were then used as model features.
Source:
characterizing circulating plasma EV size
Source:
characterizing circulating plasma EV concentration
Problem solved
It provides a reference measurement for total particle quantification against which AF4-MALS is compared.; orthogonal measurement of total particle concentration; It provides quantitative EV physical-characteristic data for non-invasive biomarker modeling in MASLD staging.; provides non-invasive measurement inputs for EV-based biomarker modeling
Source:
It provides a reference measurement for total particle quantification against which AF4-MALS is compared.
Source:
orthogonal measurement of total particle concentration
Source:
It provides quantitative EV physical-characteristic data for non-invasive biomarker modeling in MASLD staging.
Source:
provides non-invasive measurement inputs for EV-based biomarker modeling
Problem links
orthogonal measurement of total particle concentration
LiteratureIt provides a reference measurement for total particle quantification against which AF4-MALS is compared.
Source:
It provides a reference measurement for total particle quantification against which AF4-MALS is compared.
provides non-invasive measurement inputs for EV-based biomarker modeling
LiteratureIt provides quantitative EV physical-characteristic data for non-invasive biomarker modeling in MASLD staging.
Source:
It provides quantitative EV physical-characteristic data for non-invasive biomarker modeling in MASLD staging.
Published Workflows
Objective: To investigate whether circulating plasma EV characteristics, alone or combined with clinical and anthropomorphic variables, can support non-invasive MASLD steatosis staging using machine learning and explainable artificial intelligence.
Why it works: The workflow pairs non-invasive EV measurements with steatosis/fibrosis staging labels and then uses ML and XAI to learn and interpret relationships between EV and clinical features and steatosis stage.
use EV mean size and concentration as predictive biomarker featurescapture non-linear relationships between disease features and steatosis stagesnanoparticle tracking analysistransient elastography stagingmachine learning model developmentcross-validationexplainable artificial intelligenceSHAP analysis
Stages
- 1.Patient enrollment and eligibility completion(selection)
This stage defines the final analyzable cohort before measurement and modeling.
Selection: Patients with metabolic dysfunction were enrolled, then eligibility criteria and study procedure completion determined the analyzed cohort.
- 2.Non-invasive staging and EV feature acquisition(functional_characterization)
This stage generates the input labels and biomarker features required for downstream ML modeling.
Selection: Obtain steatosis/fibrosis stage labels by transient elastography and EV size/concentration features by nanoparticle tracking.
- 3.Machine learning model development(broad_screen)
This stage explores multiple model/task configurations to identify useful EV-based and multimodal classifiers.
Selection: Develop six models for S0 versus S1-S3 and fourteen models for severe steatosis identification using different feature sets.
- 4.Performance assessment and interpretability analysis(confirmatory_validation)
This stage identifies the best-performing models and explains feature-stage relationships.
Selection: Assess models using ROC-AUC, specificity, sensitivity, correlation analysis, and XAI/SHAP.
Steps
- 1.Enroll patients with metabolic dysfunction
Assemble the initial study population for MASLD-related biomarker analysis.
Enrollment is required before eligibility filtering and study measurements can occur.
- 2.Apply eligibility criteria and complete study procedures
Define the final analyzable cohort with complete data collection.
Eligibility and completion filtering narrows the cohort before feature acquisition and modeling.
- 3.Stage steatosis and fibrosis by transient elastographystaging assay
Generate steatosis and fibrosis stage information for the classification tasks.
Stage labels are needed before supervised model development.
- 4.Measure circulating plasma EV characteristics by nanoparticle trackingEV characterization assay
Generate EV size and concentration features for model input.
Feature acquisition follows cohort definition and provides the biomarker variables used in modeling.
- 5.Develop EV-only and multimodal ML models for steatosis tasksclassification models
Train models to distinguish S0 from S1-S3 and to identify severe steatosis.
Model development requires both stage labels and feature inputs from the prior measurement stage.
- 6.Evaluate model performance by repeated cross-validation
Estimate predictive performance using ROC-AUC, specificity, and sensitivity.
Performance evaluation follows model training to identify the strongest classifiers.
- 7.Interpret feature relationships using correlation analysis and SHAP/XAIinterpretability method
Explain how EV and other features relate to steatosis stages and model predictions.
Interpretability analysis is performed after model development so feature contributions can be examined on trained models.
Objective: Evaluate whether AF4-MALS-DLS can provide reliable quantity and quality assessment of VLP samples in the presence of host cell-derived impurities, and assess whether AF4-MALS can substitute for NTA for total particle quantification.
Why it works: The workflow combines AF4 separation with in-line light-scattering detectors to assess VLP quantity and quality in a label-free, rapid manner, and compares AF4-MALS readout against NTA for total particle quantification.
fractionation-based separation of particles and impurities by size-related behaviorlight-scattering-based particle quantification and sizingAF4MALSDLScomparison to nanoparticle tracking analysis
Taxonomy & Function
Primary hierarchy
Technique Branch
Method: A concrete measurement method used to characterize an engineered system.
Mechanisms
light-based particle trackingTechniques
Functional AssayTarget processes
No target processes tagged yet.
Input: Light
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationimplementation constraint: spectral hardware requirementoperating role: sensor
The method requires circulating plasma EV samples and nanoparticle tracking instrumentation or analysis capability.; requires circulating plasma EV samples
The abstract does not show that nanoparticle tracking alone establishes definitive disease staging against histopathology or advanced imaging.; the abstract does not report histopathology-validated performance of the assay-derived biomarker workflow
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
AF4-MALS is a suitable surrogate for nanoparticle tracking analysis for total particle quantification because the 90° light scattering peak area shows a strong linear correlation with total particle concentration.
correlation strength strong linear correlation
Host cell DNA, chromatin, and VLPs can co-elute in AF4-MALS-DLS because of overlapping size distributions, which can impair accurate VLP concentration and yield estimation.
AF4 coupled with in-line detectors such as UV and MALS is a promising label-free and rapid approach to simultaneously assess the quantity and quality of VLP samples.
Hydrodynamic radius characterization by AF4-MALS-DLS depends on particle concentration and method parameters, especially detector flow rate, and high detector flow rates can underestimate hydrodynamic radius.
AF4 methods require further optimization to better separate VLPs from host cell impurities and ensure reliable characterization in complex mixtures.
Using AF4-MALS instead of nanoparticle tracking analysis enables faster sample processing and reduces sample volume requirements.
Approval Evidence
2 sources2 linked approval claimsfirst-pass slug nanoparticle-tracking-analysis
circulating plasma EV characteristics were analyzed through nanoparticle tracking.
Source:
AF4-MALS was shown to be a suitable surrogate for nanoparticle tracking analysis, as the 90° light scattering peak area exhibited a strong linear correlation with total particle concentration.
Source:
benchmark comparisonsupports
AF4-MALS is a suitable surrogate for nanoparticle tracking analysis for total particle quantification because the 90° light scattering peak area shows a strong linear correlation with total particle concentration.
Source:
practical advantagesupports
Using AF4-MALS instead of nanoparticle tracking analysis enables faster sample processing and reduces sample volume requirements.
Source:
Comparisons
Source-stated alternatives
The abstract presents AF4-MALS as a suitable surrogate for NTA for total particle quantification.; The paper contrasts this non-invasive EV characterization approach with invasive liver biopsy and notes future comparison with histopathology and advanced imaging methods.
Source:
The abstract presents AF4-MALS as a suitable surrogate for NTA for total particle quantification.
Source:
The paper contrasts this non-invasive EV characterization approach with invasive liver biopsy and notes future comparison with histopathology and advanced imaging methods.
Source-backed strengths
serves as a comparator for total particle concentration; directly used to derive EV size and concentration features in this study
Source:
serves as a comparator for total particle concentration
Source:
directly used to derive EV size and concentration features in this study
Compared with AF4-MALS-DLS
The abstract presents AF4-MALS as a suitable surrogate for NTA for total particle quantification.
Shared frame: source-stated alternative in extracted literature
Strengths here: serves as a comparator for total particle concentration; directly used to derive EV size and concentration features in this study.
Relative tradeoffs: the abstract does not report histopathology-validated performance of the assay-derived biomarker workflow.
Source:
The abstract presents AF4-MALS as a suitable surrogate for NTA for total particle quantification.
Compared with imaging
The paper contrasts this non-invasive EV characterization approach with invasive liver biopsy and notes future comparison with histopathology and advanced imaging methods.
Shared frame: source-stated alternative in extracted literature
Strengths here: serves as a comparator for total particle concentration; directly used to derive EV size and concentration features in this study.
Relative tradeoffs: the abstract does not report histopathology-validated performance of the assay-derived biomarker workflow.
Source:
The paper contrasts this non-invasive EV characterization approach with invasive liver biopsy and notes future comparison with histopathology and advanced imaging methods.
Compared with imaging surveillance
The paper contrasts this non-invasive EV characterization approach with invasive liver biopsy and notes future comparison with histopathology and advanced imaging methods.
Shared frame: source-stated alternative in extracted literature
Strengths here: serves as a comparator for total particle concentration; directly used to derive EV size and concentration features in this study.
Relative tradeoffs: the abstract does not report histopathology-validated performance of the assay-derived biomarker workflow.
Source:
The paper contrasts this non-invasive EV characterization approach with invasive liver biopsy and notes future comparison with histopathology and advanced imaging methods.
Ranked Citations
- 1.